Checkpoint inhibitors in relapsed refractory Hodgkin Lymphoma
Expert: Astrid Pavlovsky, Clinical Research Center - FUNDALEU, Buenos Aires, Argentina 1 - Why do chemorefractory patients respond to checkpoint inhibitors? 2 - Can you comment on the design and results of the KEYNOTE 204 for patients with RR HL? 3 - What do you think are the future challenges and therapeutic options in this group of patients?